Y. Gu

Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment

Alexa B. Kimball, Gregor B. E. Jemec, Min Yang et al. · British Journal of Dermatology · 2014 · 207 citations

Medicine, Clinical Sciences, Dermatology +15

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study

Alexa B. Kimball, Jeffrey M. Sobell, Christos C. Zouboulis et al. · Journal of the European Academy of Dermatology and Venereology · 2015 · 193 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study

Lin Cai, Jie Gu, Jie Zheng et al. · Journal of the European Academy of Dermatology and Venereology · 2016 · 99 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Long‐term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open‐label extension study

Kim Papp, Alan Menter, Yves Poulin et al. · Journal of the European Academy of Dermatology and Venereology · 2012 · 59 citations

Pharmacy, Dermatology, Pharmacotherapy +17

Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials

Gregor B. E. Jemec, Martin M. Okun, Seth Forman et al. · British Journal of Dermatology · 2019 · 57 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13